NCT00162188No Longer Available不适用
Canadian Sustiva Oral Liquid Expanded Access Program: An Open-Label, Multicenter Expanded Access Study of the Liquid Formulation of Sustiva (Efavirenz, DMP266)
Bristol-Myers Squibb1 个研究点 分布在 1 个国家开始时间: 2001年5月最近更新:
适应症
相关药物
试验速览
- 阶段
- 不适用
- 状态
- No Longer Available
- 发起方
- 试验地点
- 1
研究概览
简要总结
This study is being conducted to assess the safety and tolerability of an oral liquid solution of Sustiva for antiretroviral therapy-naive or therapy-experienced HIV-1 infected children between the ages of 3-16 who are failing or intolerant of their current antiretroviral regimen and who are unable to swallow Sustiva capsules.
研究设计
- 研究类型
- Expanded Access
入排标准
- 年龄范围
- 3 Years 至 16 Years（Child）
- 性别
- All
- 接受健康志愿者
- 否
入选标准
- •Children 3-16 years of age
- •Anti-retroviral naive or experienced
- •Failing or intolerant to current anti-retroviral (ARV) regimen
- •Limited available viable therapeutic options
- •Inability to take capsules/tablets
排除标准
- •Weighs less than 10 kg
- •Failure on or concomitant use of other non-nucleoside reverse transcriptase inhibitors (NNRTIs)
- •An active AIDS-defining opportunistic infection or disease
- •More than two episodes of moderate to severe diarrhea or vomiting lasting more than four days within the past three months
研究者
研究点 (1)
Loading locations...
相似试验
No Longer Available
不适用
An Expanded Access Study of Oral Liquid Efavirenz in the Treatment of Children With HIV InfectionHIV InfectionNCT00162227Bristol-Myers Squibb
Unknown
不适用
Pilot Study to Assess Tolerability and Feasibility of Oral Sulfate Solution (SUPREP) in Hospitalized PatientsInpatient ColonoscopyOral Sulfate SolutionPolyethelene GlycolNCT04504292University of Virginia124
已完成
1 期
A Phase 1 Bioavailability Study of Topiramate Oral Liquid Formulation Compared to the Marketed Sprinkle Capsule Formulation in Healthy AdultsEpilepsyNCT00701493Johnson & Johnson Pharmaceutical Research & Development, L.L.C.40
终止
1 期
Phase I Study to Assess the Safety, Tolerability, and Pharmacokinetics of Orally Administered CUDC-101 in Cancer PatientsCancerNCT01702285Curis, Inc.3
已完成
2 期
A Long Term Safety Study of BCX7353 in Hereditary AngioedemaHAEProphylaxisHereditary AngioedemaNCT03472040BioCryst Pharmaceuticals387